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Cell Facts 
 GCNIS cells arise from blocked fetal germ cell differentiation 
 GCNIS cells persist in the neonatal and adult testis in a dormant, non-proliferative state 
 GCNIS invariably give rise to type II testicular germ cell tumors (seminoma and non-
seminoma) 
 Risk factors for GCNIS are infertility, cryptorchidism, defects in sex development and 
family history 
 Novel markers of GCNIS are being developed to detect the neoplasm in blood serum 
and semen of patients 
 
Abstract 
Germ cell neoplasia in situ is the non-invasive precursor cell of origin for type II testicular germ 
cell tumors. It has long been postulated that germ cell neoplasia in situ is derived from defective 
germ cell development during embryonic life, and although it is impossible to trace in vivo the 
progression from fetal germ cell to germ cell neoplasia in situ to tumor, there is a large volume 
of evidence supporting this theory. Current studies focus on understanding how germ cell 
neoplasia in situ forms, how these cells are activated at puberty and how they transform to 
invasive tumors of various subtypes. Such information is informing novel diagnostic and 
therapeutic options. 
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1. Introduction 
During early embryonic development, primordial germ cells move from a highly pluripotent 
state into a differentiated state, concommittant with their sex-specific differentiation into 
spermatogonia or oocytes. Occasionally, germ cells (also known as gonocytes) in the 
developing testis retain their pluripotency and fail to differentiate into spermatogonia. It is 
postulated that these maturation-blocked XY germ cells remain dormant throughout childhood, 
but following puberty re-initiate proliferation and possess the capacity to transform into 
invasive seminoma and non-seminoma germ cell tumors (GCT) of the testis, known collectively 
as Type II testicular GCT. The defective germ cells are called germ cell neoplasia in situ 
(GCNIS) (Moch et al., 2016).  
 
1.1 Nomenclature 
The recent WHO classification of GCNIS replaces other long-held descriptions including 
Carcinoma in situ (CIS) and intratubular germ cell neoplasia unclassified (ITGNU), as well as 
less common designations including testicular intraepithelial neoplasia (TIN) and gonocytoma 
in situ (Moch et al., 2016). 
 
1.2 Morphological features 
In testicular biopsy, GCNIS cells are found confined within seminiferous tubules that typically 
lack normal spermatogenesis and often have a thickened peritubular basement membrane and 
reduced tubule diameter (Skakkebaek, 1972). In adult testes, GCNIS cells are located basally 
and the surrounding Sertoli cells displaced luminally, however in testes of young children 
GCNIS is found both centrally and basally within the seminiferous tubules (Jorgensen et al., 
2015). GCNIS cells are distinguishable by an abundant vacuolated cytoplasm and an enlarged 
irregular nucleus measuring an average of 10µm compared to a normal spermatogonia average 
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of 6µm.  GCNIS are hyperchromatic with DNA content comparable to a tetraploid cell and 
typically have 1 or 2 prominent nucleoli (Skakkebaek, 1978) (Figure 1).  
 
1.3 Discovery 
Today we have ample evidence that GCNIS is the intermediary cell between a fetal/neonatal 
germ cell and GCT, however prior to its identification there were many theories regarding the 
cell of origin for testicular tumors. 
 
As far back as the late 1800s, the notion existed that GCT originated from germ cells. In 1911 
James Ewing asserted this case, while largely arguing against earlier theories of teratoma 
origins which included derivation from epithelia of testicular connective tissue, fetus in fetu, 
abnormal development of testicular oocytes that subsequently undergo parthenogenesis, 
fertilization of a polar body, embryonic blastomere retention, Wolffian duct derivation, and, 
lastly, adrenal rest cell derivation (Ewing, 1911) and (reviewed by Damjanov, 1991).  
 
Fifty years later, experimental evidence that teratomas arose from germ cells was discovered in 
mice. In 1954 the 129Sv-mouse strain was revealed to spontaneously produce teratomas and, 
subsequently, that teratoma incidence was greatly reduced in mice lacking germ cells (Stevens, 
1967). Because mice develop teratomas but not other germ cell neoplasias seen in humans 
(seminoma, embryonal carcinoma), it was another two decades before GCNIS was discovered. 
 
In 1972 Neils Skakkebaek described a possible ‘carcinoma in situ’ of the human testis 
(Skakkebaek, 1972). The GCNIS cells were identified as ‘atypical germ cells’ in biopsies of 
two infertile patients, who, within 4.5 years after primary analysis, had developed embryonal 
carcinoma. Subsequently, GCNIS cells were identified in pre-pubertal males and found in close 
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association with both seminoma and non-seminoma tumors in up to 98% of cases analyzed 
(Jacobsen et al., 1981).  
 
2. Cell Origin and Plasticity 
Once the existence of GCNIS and the implications for embryonal carcinoma had been 
documented, the origin of this cancer precursor was explored. Although it is impossible to 
linage trace its genesis in real time or even in rodent models, there is sufficient epidemiological, 
cytogenetic and molecular evidence to indicate that GCNIS arises from a fetal germ cell 
arrested in its development.  
 
2.1 Normal germ cell development 
During early fetal development, gonadal germ cells are located centrally within the 
seminiferous tubule, have an un-methylated genome, and express markers of pluripotency 
(OCT3/4, NANOG), as well as PLAP, KIT and Ki-67. Beginning in late gestation (gestational 
week 17-18) to neonatal life (until about 1 year), expression of fetal markers is lost and 
differentiation markers, including MAGE4A and TSPY, become expressed (Pauls et al., 2006). 
Further, de novo methylation occurs, to establish parental specific imprinting. During this 
transition, germ cells, now referred to as spermatogonia, migrate peripherally to the basement 
membrane and enter mitotic quiescence. The differentiation process of gonotye-to-
spermatogonia occurs asynchronously within the population such that in any given tubule germ 
cells can be found expressing fetal markers, differentiation markers, methylated or un-
methylated DNA and combinations thereof. 
 
2.1 Defective germ cell development seeds GCNIS 
Germ cells that fail to differentiate, presumably because of either incorrect somatic cues or an 
innate inability to respond correctly to these cues, retain pluripotency marker expression, fail 
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to differentiate and remain quiescent until puberty. In response to hormonal stimulation at 
puberty GCNIS cells resume proliferation, which is dependent on Sertoli cell-derived growth 
and survival signals and testosterone produced by Leydig cells, and gradually replace normal 
spermatogonia within affected tubules (Almstrup et al., 2007). Gain of chromosomal 
abnormalities over time in GCNIS (discussed below) leads to the establishment of Sertoli cell-
independent proliferation and, thus, malignant potential (reviewed by Looijenga et al., 2003). 
 
Molecular evidence that GCNIS is derived from a fetal gonocyte is found in shared gene 
expression and methylation status (Almstrup et al., 2007; Clark et al., 2004). Indeed, the gene 
expression profile of GCNIS and fetal germ cells differed for only 5 genes in one gene 
expression study (Sonne et al., 2009). In particular, PLAP, KIT, OCT3/4 and Ki-67 are 
expressed in GCNIS, lending support to the hypothesis that it arises from a fetal gonocyte 
(Honecker et al., 2004). Further, the low level of DNA methylation in GCNIS is thought to 
reflect the stage at which the germ cell became developmentally blocked i.e. prior to the de 
novo methylation that occurs relatively late during fetal development and accompanies 
differentiation (Rijlaarsdam et al., 2015a). 
 
It is important to be able to distinguish the pre-cancerous GCNIS cells from germ cells with 
maturation delay, which are found more frequently in patients with disorders of sex 
development (DSD) and trisomy 21 (Cools et al., 2005). In this situation, dimorphic expression 
of pluripotency marker OCT3/4, SCF, TSPY and the location of these cells centrally within the 
tubule is used to distinguish maturation delay from GCNIS (Stoop et al., 2008).  
 
3. Functions 
GCNIS has no ‘normal’ function in the pre- or post-pubertal male. GCNIS cells are found in 
0.4 – 0.8% of the male population and the presence of these cells causes reduced or absent 
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spermatogenesis. It is expected that all GCNIS will progress to seminoma and/or non-seminoma 
over time. Indeed, the incidence of GCNIS prevalence is equivalent to the lifetime incidence of 
germ cell tumours in the general population, assessed in both Germany and Denmark 
(Giwercman et al., 1991; Linke et al., 2005). Because progression to tumorigenesis is relatively 
slow, it is expected that 70% of GCNIC-positive patients will develop seminoma and/or non-
seminoma neoplasia within 7 years (Giwercman and Skakkebaek, 1993).  
 
4. Associated Pathologies 
The presence of GCNIS is asymptomatic and is usually not diagnosed until an overt tumor has 
developed. GCNIS is the precursor lesion for two histologically distinct GCT sub-types: 
seminoma and non-seminoma. Triggers for GCNIS malignant transformation as well as current 
and emerging therapies for treatment and diagnosis of the disease are discussed below. 
 
4.1 Triggering malignant development 
Although present from birth, GCNIS do not become malignant until after puberty. 
Consequently, the incidence of GCT increases shortly after puberty and the median age at 
diagnosis is 35 years. It is not known definitively whether malignant capacity exists from 
inception, though it seems likely that a second ‘hit’ in the form of chromosomal aberrations is 
required to reach this potential. Gain of the short arm of chromosome 12 (or smaller parts 
thereof) is present in an estimated 80-100% of invasive seminoma and non-seminoma tumors 
and also in GCNIS cells adjacent to these neoplasms (Summersgill et al., 2001). GCNIS cells 
that are not in the physical vicinity of tumorigenic lesions generally lack short arm of 
chromosome 12 gain, suggesting that it is a key transformative event. This chromosomal region 
harbors a 200-kb gene cluster containing bona fide stem cell-related genes NANOG, STELLA 
and GDF3, which are also expressed and associated with pluripotency in human ES cells, and 
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presumably similarly promote pluripotency in GCNIS (Clark et al., 2004). In GCNIS cells 
associated with invasive seminoma and non-seminoma there is also a typical gain of material 
from chromosomes 1,5,7,8,12 and X and lack of material from 4 and 13 (Summersgill et al., 
2001).  
 
4.2 Risk factors for GCNIS 
Given the fetal origins of GCNIS, factors that adversely affect gonadal and germ cell 
development increase the risk of developing GCNIS and GCT. Risk factors include familial 
predisposition, subfertility, cryptorchidism, disorders of sex development, high maternal 
estrogen, in utero exposure to environmental toxins with estrogenic activity and prior history 
of GCT (reviewed by Rajpert-De Meyts et al., 2016). Of these risk groups, there has been 
considerable research into patients with DSD, which encompasses a wide array of anomalies 
categorized into three groups: 46,XY DSD, 46,XX DSD and sex chromosome DSD. Many 
factors beyond karyotype contribute to the individual’s resulting gonadal morphology and 
secondary sexual characteristics and as such risk factors for GCNIS and GCT should be 
assessed on a case-by-case basis. Generally however, those with 46,XY DSD and 45,X/46,XY 
sex chromosome DSD, harboring varying degrees of gonadal dysgenesis have highest risk of 
GCT, within the range of 15-30% (for a comprehensive review see Jorgensen et al., 2015). 
 
4.3 Pathways of transformation 
As discussed, various genetic and environmental transformative events are required to 
transform GCNIS cells into seminoma or non-seminoma GCT. Exactly what determines 
GCNIS transformation into either, or both, pathologies is not known. Certain genetic mutations, 
including activating mutations to KIT are more highly associated with seminomas (Tian et al., 
1999), indicating that specific genetic aberrations accumulated by GCNIS are a key step to 
defining tumorigenic pathology. Furthermore, there is also uncertainty as to whether GCNIS 
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progression to embryonal carcinoma is direct or whether it occurs via prior transformation into 
seminoma (Figure 2). It is generally accepted, however, that the differentiated forms of non-
seminoma (yolk sac tumor, teratoma and choriocarcinoma) derive from invasive embryonal 
carcinoma. Given that GCNIS cells are relatively homogeneous in marker expression and 
methylation status, and that seminoma and non-seminoma tumors are sometimes found within 
a single biopsy, it seems likely that both pathways of GCNIS transformation can occur; the 
pathway undertaken presumably depends on circumstances, including the presence of risk 
factors and the status of susceptibility genes.  
 
4.4 Current therapies 
 
GCNIS cells are radiation-sensitive so scrotal irradiation prevents GCNIS malignant 
transformation (von der Maase et al., 1986). The majority of GCNIS-derived tumors are 
detected whilst confined to the testis (Stage I) and therefore have a high cure rate following 
testis removal (80% for seminoma, 60% for non-seminoma). Follow-up for stage I tumors 
involves active surveillance, including imaging. The current relapse rate for seminoma is 
around 13% however this can be reduced to around 4% with a single dose of chemotherapy 
(Chau et al., 2015). Non-seminomas have a recurrence rate as high as 30%, leading many 
clinicians to recommend pre-emptive chemotherapy and often retroperitoneal lymph node 
dissection. The response of non-seminomas to chemotherapy treatment is varied based on 
histology and occasionally chemotherapy resistance can develop with low survival rates (30-
50%) (reviewed by Rajpert-De Meyts et al., 2016).  
 
Although GCT has a high cure rate, the treatment-related morbidity for radiotherapy (infertility, 
cardiovascular disease) and chemotherapy (renal impairment, pulmonary toxicity, vascular 
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disease, infertility) is a significant problem because of the relative youth of survivors 
(Pliarchopoulou and Pectasides, 2010). 
 
4.5 New approaches 
GCNIS is asymptomatic, hence diagnosis usually occurs after GCT transformation. Testicular 
biopsy is the current gold standard method for diagnosis, however false negative results can 
occur because GCNIS cells are not always randomly distributed throughout the entire testis 
(van Casteren et al., 2008a). It would be vastly preferable to identify and treat GCNIS before 
neoplasias develop in order to minimise long-term side effects of treatment. Because some 
GCNIS (and tumor) cells can be exfoliated and subsequently detected within semen of patients, 
attempts to detect GCNIS and tumors using this non-invasive approach have been made. To 
date studies have detected GCNIS cells in semen by virtue of AP-2 OCT3/4, M2A/PDPN, 
MAGE-A4 and NY-ESO-1 expression, although these had relatively low sensitivity (Hoei-
Hansen et al., 2007; Satie et al., 2009; van Casteren et al., 2008b). The presence of micro-RNAs 
(specifically miR-302, miR367 and miR371-3, which are highly expressed in GCNIS) have 
been detected in blood serum of patients with good sensitivity (Dieckmann et al., 2012; 
Rijlaarsdam et al., 2015b). Most recently, a cell surface receptor TDGF-1 (CRIPTO) was 
detected in blood serum of patients with GCNIS and various tumor subtypes (Spiller et al., 
2016). For the purposes of detection of GCNIS in semen TDGF1 may be a better candidate 
than the transcription factors mentioned above: this is due to its ability to be cleaved from the 
cell surface and, therefore, to be detectable irrespective of the presence of GCNIS or tumor 
cells.  
 
Combination therapies combining chemotherapy with molecular inhibitors may be the most 
promising new approach for treatment of chemotherapy-resistant non-seminomas. In vitro 
studies have shown that the sensitivity of embryonal carcinoma cell lines to chemotherapy can 
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be augmented by treatment with an inhibitor to MDM2 (Bauer et al., 2010) or by delivery of 
miR-302a (Liu et al., 2013). Obviously, such targets will be most feasible for practical 
application if they have strong expression in cancer tissue but show weak or no activity in 
normal tissue. As we continue to understand the molecular pathways governing GCNIS genesis 
and malignant transformation, new targets for detection and therapy will emerge.  
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Figure Legends 
 
Figure 1. Histology of normal spermatogenic and GCNIS-containing tubules. GCNIS cells 
stained for CRIPTO expression (brown cytoplasmic staining), counterstained with 
Haematoxylin. 
 
Figure 2. Pathways of GCNIS transformation into seminoma and non-seminoma germ 
cell tumors. Evidence suggests GCNIS can transform into either seminoma or embryonal 
carcinoma. The differentiated forms of non-seminoma (yolk sac tumor, teratoma and 
choriocarcinoma) arise from embryonal carcinoma. 
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